CSL889 is a new potential treatment under development for the symptoms of SCD.
CSL889 is a plasma derived Hemopexin, an important protein produced naturally in the body whose levels are decreased in patients with SCD.
CSL889 will be developed for the treatment of acute vasoocclusive crisis, a severe and painful complication in SCD patients.
It is given via blood channels (veins) over a period of approx. 1 hour or less.
- This is a clinical research study involving a single administration of the study drug, CSL889
- This is the first time that the study drug is being given to humans.
- This study will run for approximately 54 days
- This involves 9 outpatient visits and a 2 night residential stay
- Eligible participants may receive compensation for their participation in the study, plus reasonable travel expenses.
- Approx. 24 participants will take part in the study
Currently Open Clinical Trial Locations:
- King’s College Hospital – Denmark Hill London SE5 9RS
- Guy’s & St Thomas Hospital – Great Maze Pond London SE1 9RT
- MAC’s Early Phase Unit – Nelson Street Manchester M13 9NQ
If you are interested in this trial, you can also speak to your treating physicians who can get in touch with the participating sites on your behalf.